Deep Learning Empowers Lung Cancer Screening Based on Mobile Low-Dose Computed Tomography in Resource-Constrained Sites.

BACKGROUND Existing challenges of lung cancer screening included non-accessibility of computed tomography (CT) scanners and inter-reader variability, especially in resource-limited areas. The combination of mobile CT and deep learning technique has inspired innovations in the routine clinical practice. METHODS This study recruited participants prospectively in two rural sites of western China. A deep learning system was developed to assist clinicians to identify the nodules and evaluate the malignancy with state-of-the-art performance assessed by recall, free-response receiver operating characteristic curve (FROC), accuracy (ACC), area under the receiver operating characteristic curve (AUC). RESULTS This study enrolled 12,360 participants scanned by mobile CT vehicle, and detected 9511 (76.95%) patients with pulmonary nodules. Majority of participants were female (8169, 66.09%), and never-smokers (9784, 79.16%). After 1-year follow-up, 86 patients were diagnosed with lung cancer, with 80 (93.03%) of adenocarcinoma, and 73 (84.88%) at stage I. This deep learning system was developed to detect nodules (recall of 0.9507; FROC of 0.6470) and stratify the risk (ACC of 0.8696; macro-AUC of 0.8516) automatically. CONCLUSIONS A novel model for lung cancer screening, the integration mobile CT with deep learning, was proposed. It enabled specialists to increase the accuracy and consistency of workflow and has potential to assist clinicians in detecting early-stage lung cancer effectively.

[1]  Wei-min Li,et al.  Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images , 2022, Frontiers in Immunology.

[2]  Wei-min Li,et al.  Deep Learning to Predict EGFR Mutation and PD-L1 Expression Status in Non-Small-Cell Lung Cancer on Computed Tomography Images , 2021, Journal of oncology.

[3]  Jie He,et al.  Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. , 2021, The Lancet. Public health.

[4]  H. Aerts,et al.  Artificial intelligence for clinical oncology. , 2021, Cancer cell.

[5]  Joe Y. Chang,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  Jie He,et al.  Cancer incidence and mortality in China, 2015 , 2020, Journal of the National Cancer Center.

[7]  Dan Liu,et al.  Deep learning for predicting subtype classification and survival of lung adenocarcinoma on computed tomography , 2021, Translational oncology.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  Wei-min Li,et al.  Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images , 2021, Theranostics.

[10]  M. Oudkerk,et al.  Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives , 2020, Nature Reviews Clinical Oncology.

[11]  R. Cardarelli,et al.  Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society Statement , 2020, American journal of respiratory and critical care medicine.

[12]  Fanshuang Zhang,et al.  Lung Cancer in People's Republic of China. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  R. Barzilay,et al.  Deep learning to estimate RECIST in patients with NSCLC treated with PD-1 blockade. , 2020, Cancer discovery.

[14]  R. Booton,et al.  Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk , 2020, BMJ Open.

[15]  Zhang Yi,et al.  The application of artificial intelligence and radiomics in lung cancer , 2020, Precision clinical medicine.

[16]  H. Wang,et al.  Development and clinical application of deep learning model for lung nodules screening on CT images , 2020, Scientific Reports.

[17]  W. Liang,et al.  Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography , 2020, Cell.

[18]  Zhang Yi,et al.  DeepLN: A framework for automatic lung nodule detection using multi-resolution CT screening images , 2020, Knowl. Based Syst..

[19]  Harry J de Koning,et al.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. , 2020, The New England journal of medicine.

[20]  Reid F Thompson,et al.  Artificial Intelligence in Radiation Oncology. , 2019, Hematology/oncology clinics of North America.

[21]  S. Plevritis,et al.  Cost-Effectiveness Analysis of Lung Cancer Screening in the United States , 2019, Annals of Internal Medicine.

[22]  Ahmedin Jemal,et al.  Cancer treatment and survivorship statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[23]  G. Corrado,et al.  End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography , 2019, Nature Medicine.

[24]  Andre Esteva,et al.  A guide to deep learning in healthcare , 2019, Nature Medicine.

[25]  Sameer Antani,et al.  Implementing a mobile diagnostic unit to increase access to imaging and laboratory services in western Kenya , 2018, BMJ Global Health.

[26]  Ning Wang,et al.  Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. , 2018, The Lancet. Global health.

[27]  Andrew H. Beck,et al.  Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer , 2017, JAMA.

[28]  M. Jantz,et al.  The American College of Radiology Lung Imaging Reporting and Data System: Potential Drawbacks and Need for Revision , 2017, Chest.

[29]  P. V. van Ooijen,et al.  Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. , 2016, The Lancet. Oncology.

[30]  N J Wald,et al.  UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening , 2015, Thorax.

[31]  E. Kazerooni,et al.  Performance of Lung-RADS in the National Lung Screening Trial , 2015, Annals of Internal Medicine.

[32]  Arash Naeim,et al.  Cost-effectiveness of CT screening in the National Lung Screening Trial. , 2014, The New England journal of medicine.

[33]  S. Rosso,et al.  Quality of information and cancer care planning in China: a commentary to the report of cancer incidence and mortality in China. , 2014, Annals of translational medicine.

[34]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .